Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Post by GrahamBon Oct 10, 2021 9:39pm
350 Views
Post# 33994324

FSD Delisting?

FSD Delisting?Really interesting article over an equity guru, that summarizes nicely the horrible failure, missed opportunities, executive miss management

Here are a few choice quotes:


Is FSD Pharma (HUGE.N) getting into psychedelics to avoid being kicked off the Nasdaq?

 

 “

The company filed an Investigational IND with the FDA in August 2020 and was given the green light just a month later to initiate a phase 2 clinical trial for the use of FSD201 to treat COVID-19. But last month announced they were terminating the study. Another L for FSD Pharma. Can we please change this company’s name to SMDH Pharma. They were cannabis, then they were Covid, now they are psychedelics. They can’t seem to make up their mind, it all feels pretty random and fly by night.”

 

They also seem to burn their bridges after each phase instead of integrating a series of different verticals under one rooftop kind of like Revive (RVV.C) did. It’s been a bizarre strategy and the company’s share price has been nothing more than a flatline with the occasional blip for years now. Whatever trend comes after psychedelics I wouldn’t surprised to see another pivot, CEO, rollback, etc”

 

“FSD Pharma announced back in August it was acquiring 100% of the issued and outstanding shares Lucid Psycheceuticals Inc. (“Lucid”), a Canadian-based specialty psychedelic pharmaceutical company focused on the development of therapies to treat critical neurodegenerative diseases, for roughly $11.3 million CAD in FSD Pharma stock. Prof. Lakshmi Kotra, co-founder and CEO of Lucid, commented, “We started with a vision to accelerate therapies for Total Brain Health.” My counter to that would be, you just took $11.3 million CAD in FSD shares “

 

https://equity.guru/2021/09/20/no-one-is-excited-about-fsd-pharma-huge-n-getting-into-psychedelics/

 

<< Previous
Bullboard Posts
Next >>